AptaBio Therapeutics (Korea) Performance
| 293780 Stock | 5,860 180.00 2.98% |
On a scale of 0 to 100, AptaBio Therapeutics holds a performance score of 4. The firm shows a Beta (market volatility) of 0.38, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, AptaBio Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding AptaBio Therapeutics is expected to be smaller as well. Please check AptaBio Therapeutics' total risk alpha, maximum drawdown, potential upside, as well as the relationship between the treynor ratio and value at risk , to make a quick decision on whether AptaBio Therapeutics' price patterns will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in AptaBio Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, AptaBio Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Total Cashflows From Investing Activities | 1.1 B |
AptaBio |
AptaBio Therapeutics Relative Risk vs. Return Landscape
If you would invest 550,000 in AptaBio Therapeutics on March 2, 2024 and sell it today you would earn a total of 54,000 from holding AptaBio Therapeutics or generate 9.82% return on investment over 90 days. AptaBio Therapeutics is generating 0.2228% of daily returns and assumes 3.7563% volatility on return distribution over the 90 days horizon. Simply put, 33% of stocks are less volatile than AptaBio, and 96% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
AptaBio Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AptaBio Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AptaBio Therapeutics, and traders can use it to determine the average amount a AptaBio Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0593
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 293780 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.76 actual daily | 33 67% of assets are more volatile |
Expected Return
| 0.22 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average AptaBio Therapeutics is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AptaBio Therapeutics by adding it to a well-diversified portfolio.
AptaBio Therapeutics Fundamentals Growth
AptaBio Stock prices reflect investors' perceptions of the future prospects and financial health of AptaBio Therapeutics, and AptaBio Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AptaBio Stock performance.
| Return On Equity | -17.47 | |||
| Return On Asset | -0.0568 | |||
| Operating Margin | (17.13) % | |||
| Current Valuation | 794.49 B | |||
| Shares Outstanding | 10.88 M | |||
| Price To Sales | 926.14 X | |||
| Revenue | 223.68 M | |||
| EBITDA | (6.58 B) | |||
| Cash And Equivalents | 6.57 B | |||
| Total Debt | 46.77 M | |||
| Cash Flow From Operations | (8.9 B) | |||
| Total Asset | 64.91 B | |||
About AptaBio Therapeutics Performance
To evaluate AptaBio Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when AptaBio Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare AptaBio Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand AptaBio Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents AptaBio's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Things to note about AptaBio Therapeutics performance evaluation
Checking the ongoing alerts about AptaBio Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AptaBio Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AptaBio Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the revenue of 223.68 M. Net Loss for the year was (10.69 B) with profit before overhead, payroll, taxes, and interest of 336.97 M. | |
| AptaBio Therapeutics has accumulated about 6.57 B in cash with (8.9 B) of positive cash flow from operations. | |
| Roughly 34.0% of the company shares are owned by insiders or employees |
- Analyzing AptaBio Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AptaBio Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining AptaBio Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AptaBio Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of AptaBio Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AptaBio Therapeutics' stock. These opinions can provide insight into AptaBio Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AptaBio Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the AptaBio Therapeutics information on this page should be used as a complementary analysis to other AptaBio Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for AptaBio Stock analysis
When running AptaBio Therapeutics' price analysis, check to measure AptaBio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AptaBio Therapeutics is operating at the current time. Most of AptaBio Therapeutics' value examination focuses on studying past and present price action to predict the probability of AptaBio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AptaBio Therapeutics' price. Additionally, you may evaluate how the addition of AptaBio Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |